|
|
8/9/2006 11:32:40 AM ET News Release Index
SWISS MEDICA LAUNCHES O24™ PRIVATE LABEL PRODUCT WITH SIERRASIL®
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
August 9, 2006
Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) announced today that the Sierra Mountain Minerals of
Vancouver, British Columbia has incorporated Swiss Medica’s patented O24™ Pain Neutralizer into their new
SierraSil® mineral formulation called: “SierraSil Pain Relief Formula”. This new topical private label product
offers the safe, quick and effective pain relief of O24™ and the arthritic healing attributes of SierraSil®. SierraSil
Pain Relief Formula will be available nationwide in leading natural health retailers across Canada and the United
States.
According to Grant Johnson, Swiss Medica’s President and COO: “We are excited to be working with Sierra
Mountain Minerals as we believe this new product offering will offer enhanced pain relief efficacy – both short
term and medium term. In addition, this new sales and distribution opportunity will enable us to expand our
reach, open new markets and expand our clinical research regarding the amazing properties of both O24™ Pain
Neutralizer and SierraSil®.”
According to Michael Bentley, EVP of Sierra Mountain Minerals: “We are pleased to be part of the Swiss Medica
team. Over the last two years SierraSil® has been added to a number of new and innovative products for joint
health, pain relief and many more. Swiss Medica's extraordinary research, their patented formulas and excellent
marketing team makes them a great partner for SierraSil®. We look forward to a long and prosperous
relationship.”
About SierraSil®
SierraSil® is a distinct, naturally-occurring mineral composite found only in the high Sierra Mountains. SierraSil®
has been clinically shown to protect cartilage from breakdown and daily wear and tear by up to 73 percent and,
unlike other nutraceuticals, suppresses gene expression associated with inflammatory responses.
About Sierra Mountain Minerals, Inc.
Was founded in 2003 by Peter and Michael Bentley to provide its proprietary new mineral supplement SierraSil®
to those needing fast-acting, powerful joint and cartilage support, Sierra Mountain Minerals has experienced
rapid growth in North America. Their products are available throughout the US and Canada and fine health food
stores. Peter Bentley is the President of Sierra Mountain Minerals and is the Chairman of the Board of Canfor
Corporation, a C$3.7 billion revenue publicly traded forestry product company (CFP on the Toronto Stock
Exchange) and also served for many years as a director of Bank of Montreal and Shell Canada Ltd. Michael
Bentley, the Company’s Chief Operations Officer, has held a variety of management positions at a leading forest
products company. He has a Master of Science in Management from Stanford. He is also a member of the
Institute of Corporate Directors and serves on a variety of business and not-for-profit boards.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-
tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through
innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in
the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our
websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare
professionals and athletes in the United States, Canada and in Europe. O24™ is widely available over-the-
counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can
also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1)
over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded
O24 Fibromyalgia™ their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain
associated with fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 percent of the
patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 percent who
used the placebo. Customers can also visit www.O24zone.com for ordering details and store locators for the
nearest retailer.
Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is
a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in
mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
For more information, please contact:
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
1-866-485-4243
djones@swissmedica.com
|
|
